Rosmantuzumab (INN;[1] development code OMP-131R10) is a humanized monoclonal antibody designed for the treatment of cancer.[2][3][4]
This drug was developed by OncoMed Pharmaceuticals.[5]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.